Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thyroid papillary carcinoma after alemtuzumab therapy for MS.

× No keyword cloud information.

4 in total

Review 1. Low risk papillary thyroid cancer.

Authors: Juan P Brito; Ian D Hay; John C Morris
Journal: BMJ Date: 2014-06-16

2. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors: Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal: Lancet Date: 2012-11-01 Impact factor: 79.321

3. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

Authors: Lindsey Enewold; Kangmin Zhu; Elaine Ron; Aizen J Marrogi; Alexander Stojadinovic; George E Peoples; Susan S Devesa
Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-24 Impact factor: 4.254

4. The increasing incidence of thyroid cancer: the influence of access to care.

Authors: Luc G T Morris; Andrew G Sikora; Tor D Tosteson; Louise Davies
Journal: Thyroid Date: 2013-04-18 Impact factor: 6.568

4 in total

6 in total

Review 1. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.

Authors: Eva Havrdova; Dana Horakova; Ivana Kovarova
Journal: Ther Adv Neurol Disord Date: 2015-01 Impact factor: 6.570

Review 2. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors: Babak Soleimani; Katy Murray; David Hunt
Journal: Drug Saf Date: 2019-08 Impact factor: 5.606

Review 3. Alemtuzumab for Multiple Sclerosis.

Authors: Mark D Willis; Neil P Robertson
Journal: Curr Neurol Neurosci Rep Date: 2016-09 Impact factor: 5.081

Thyroid papillary carcinoma after alemtuzumab therapy for MS.